[Therapeutic trial in acute cochlear deafness. A comparative study of Ginkgo biloba extract and nicergoline].
Ischemia and the metabolic disorder it entails would seem to be the pathogenic mechanism behind acute cochlear deafness, irrespective of the triggering process. The prognosis is entirely dependent on the rapid initiation of an effective treatment. At the end of a double-blind therapeutic trial comparing Ginkgo biloba extract and a standard alpha blocker (nicergoline), a significant recovery was observed in both therapeutic groups, but improvement was distinctly better in the Ginkgo biloba group.
D001301:Audiometry, Pure-Tone; D001302:Audiometry, Speech; D002986:Clinical Trials as Topic; D003051:Cochlea / Q000098:blood supply; D004873:Ergolines / Q000627:therapeutic use*; D034381:Hearing Loss / Q000188:drug therapy*; D006314:Hearing Loss, Conductive / Q000188:drug therapy*; D006801:Humans; D007511:Ischemia / Q000209:etiology; D008875:Middle Aged; D009530:Nicergoline / Q000627:therapeutic use*; D010936:Plant Extracts / Q000627:therapeutic use; D010946:Plants, Medicinal; D011897:Random Allocation; D014197:Trees
D004873:Ergolines; D010936:Plant Extracts; D009530:Nicergoline
Essai thérapeutique dans les surdités cochléaires aiguës. Etude comparative de l'extrait de Ginkgo biloba et de la nicergoline.